Treatment of Pulmonary Arterial Hypertension
For treatment-naïve PAH patients at low or intermediate risk (WHO FC II-III), initial oral combination therapy with ambrisentan plus tadalafil is superior to monotherapy and should be the preferred first-line approach. 1, 2
Risk Stratification and Initial Treatment Selection
Acute Vasoreactivity Testing
- Perform acute vasoreactivity testing in all treatment-naïve patients with idiopathic PAH, heritable PAH, or drug-induced PAH 1
- Vasoreactive patients (positive test): Initiate calcium channel blocker (CCB) therapy 1
- Non-vasoreactive patients: Proceed with risk-based treatment algorithm 1
Risk-Based Treatment Algorithm
Low or Intermediate Risk (WHO FC II-III):
- First-line: Initial oral combination therapy with ambrisentan plus tadalafil 1, 2
- Alternative monotherapy options (if combination not feasible): 2
- Phosphodiesterase-5 inhibitors: Sildenafil 20 mg TID or Tadalafil 40 mg daily
- Endothelin receptor antagonists: Bosentan 125 mg BID, Ambrisentan 5-10 mg daily, or Macitentan 10 mg daily
- Soluble guanylate cyclase stimulator: Riociguat 0.5-2.5 mg TID
High Risk (WHO FC IV):
- Initial combination therapy including intravenous prostacyclin analogues 1
- Prioritize IV epoprostenol as it has demonstrated reduced 3-month mortality in high-risk PAH patients 1
- Start at 2 ng/kg/min and increase as tolerated 2
Sequential Combination Therapy
If inadequate clinical response to initial therapy:
- Reassess at 3-4 months post-treatment initiation 3
- Sequential double or triple combination therapy is recommended 1
- Target agents from different therapeutic pathways 1
- Contraindication: Do not combine riociguat with PDE-5 inhibitors 1
Maximal medical therapy now includes four drug classes: 3
- Phosphodiesterase-5 inhibitors/soluble guanylate cyclase stimulators
- Endothelin receptor antagonists
- Prostacyclin pathway agents
- Sotatercept (approved 2024 as second-line therapy) 4, 3
Advanced and Rescue Therapies
For inadequate response on maximal medical therapy:
- Consider eligibility for lung transplantation after inadequate response to initial therapy 1
- Refer for lung transplantation soon after inadequate response is confirmed on maximal combination therapy 1
- Bilateral lung transplantation with repair of cardiac defects is the preferred approach 1
- Balloon atrial septostomy (BAS) may be considered as a palliative or bridging procedure in patients deteriorating despite maximal medical therapy (Class IIb recommendation) 1
Intensive Care Management
For critically ill PAH patients with:
- Heart rate >110 beats/min
- Systolic blood pressure <90 mmHg
- Low urine output and rising lactate 1
Management includes:
- Hospitalization in ICU is recommended (Class I) 1
- Inotropic support for hypotensive patients (Class I) 1
- Veno-arterial ECMO may be employed in awake end-stage patients for bridging to lung transplantation 1
Supportive Care
All PAH patients should receive:
- Aggressive treatment of contributing causes of pulmonary hypertension 2
- Supervised exercise activity as part of integrated care 2
- Current immunization against influenza and pneumococcal pneumonia 2
- Pregnancy avoidance 2
- Palliative care services incorporated into management 2
Common Pitfalls
- Delayed referral to expert centers: Only 5.6% of patients with pulmonary hypertension are referred to PH experts, including those with risk factors for PAH 5
- Monotherapy in treatment-naïve patients: The evidence strongly favors initial combination therapy over sequential escalation 1, 6
- Combining riociguat with PDE-5 inhibitors: This combination is contraindicated 1
- Underutilization of parenteral prostacyclins in high-risk patients: IV epoprostenol has mortality benefit in this population 1
Treatment Heterogeneity
Recent network meta-analysis demonstrates significant treatment heterogeneity based on age, body mass index, hypertension, diabetes, and coronary artery disease 6. The endothelin + nitric oxide pathway combination showed the greatest improvement in 6-minute walk distance (43.7 meters vs. placebo) 6.